Immunicum AB (publ) Clarifies Information Regarding Directed Issue
Keep reading
Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel – a New and Innovative Cancer Immunotherapy
